Evvy wants to end ambiguity in women’s care.
What’s happening: The precision diagnostics company secured a $40M Series B to integrate vaginal microbiome intelligence across women’s care.
Sure thing. Serving 100K patients and 3K practitioners, Evvy’s platform connects at-home, metagenomic vaginal health testing to personalized treatment and longitudinal outcomes.
Powered by its proprietary vaginal microbiome dataset and AI advisor, its platform delivers an accurate diagnosis to 90%+ of symptomatic patients — succeeding in a category where women typically experience 50%+ misdiagnosis rates.
Missing pieces. Using the vaginal microbiome as an overlooked biomarker, Evvy wants to surface signals standard-of-care testing has historically missed.
Beginning with fertility and extending to pre-term birth, gynaecological cancers, PMOS, menopause, and more, the opportunity represents $180B+ in underserved outcomes. Advancing diagnostics, CEO Priyanka Jain envisions its testing becoming an ultra-accessible, “new-age Pap smear.”
Looking ahead: For Evvy, every “unexplained” complication is just an incomplete picture. As women’s healthcare breaks out of silos in a shift to lifelong care, the vaginal microbiome will become a key biomarker.
